These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 34637516)

  • 1. The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.
    Bartova L; Fugger G; Dold M; Kautzky A; Swoboda MMM; Rujescu D; Zohar J; Souery D; Mendlewicz J; Montgomery S; Fabbri C; Serretti A; Kasper S
    Int J Neuropsychopharmacol; 2022 Feb; 25(2):118-127. PubMed ID: 34637516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder.
    Fugger G; Bartova L; Dold M; Fabbri C; Fanelli G; Zanardi R; Kautzky A; Zohar J; Souery D; Mendlewicz J; Montgomery S; Rujescu D; Serretti A; Kasper S
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar; 114():110480. PubMed ID: 34826558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K; Depping AM; Gaudchau A; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008121. PubMed ID: 21154393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.
    Lin CY; Tsai GE; Wang HS; Wu YH; Chiou CC; Wu VY; Lane HY
    J Clin Psychiatry; 2014 Sep; 75(9):e924-31. PubMed ID: 25295435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study.
    Dold M; Bartova L; Kautzky A; Serretti A; Porcelli S; Souery D; Mendlewicz J; Montgomery S; Zohar J; Kasper S
    Eur Neuropsychopharmacol; 2018 Dec; 28(12):1305-1313. PubMed ID: 30446357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-generation antipsychotics in major depressive disorder: update and clinical perspective.
    Chen J; Gao K; Kemp DE
    Curr Opin Psychiatry; 2011 Jan; 24(1):10-7. PubMed ID: 21088586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Seetasith A; Greene M; Hartry A; Burudpakdee C
    J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of phenelzine with aripiprazole and quetiapine in a treatment-resistant patient with psychotic unipolar depression: case report and literature review.
    Meyer JM; Cummings MA; Proctor G
    CNS Spectr; 2017 Oct; 22(5):391-396. PubMed ID: 28004621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.
    Mohamed S; Johnson GR; Chen P; Hicks PB; Davis LL; Yoon J; Gleason TC; Vertrees JE; Weingart K; Tal I; Scrymgeour A; Lawrence DD; Planeta B; Thase ME; Huang GD; Zisook S; ; Rao SD; Pilkinton PD; Wilcox JA; Iranmanesh A; Sapra M; Jurjus G; Michalets JP; Aslam M; Beresford T; Anderson KD; Fernando R; Ramaswamy S; Kasckow J; Westermeyer J; Yoon G; D'Souza DC; Larson G; Anderson WG; Klatt M; Fareed A; Thompson SI; Carrera CJ; Williams SS; Juergens TM; Albers LJ; Nasdahl CS; Villarreal G; Winston JL; Nogues CA; Connolly KR; Tapp A; Jones KA; Khatkhate G; Marri S; Suppes T; LaMotte J; Hurley R; Mayeda AR; Niculescu AB; Fischer BA; Loreck DJ; Rosenlicht N; Lieske S; Finkel MS; Little JT
    JAMA; 2017 Jul; 318(2):132-145. PubMed ID: 28697253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder.
    Bartova L; Fugger G; Dold M; Kautzky A; Fanelli G; Zanardi R; Albani D; Weidenauer A; Rujescu D; Souery D; Mendlewicz J; Montgomery S; Zohar J; Fabbri C; Serretti A; Kasper S
    J Affect Disord; 2023 Jul; 332():105-114. PubMed ID: 36958488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with the second-generation antipsychotic quetiapine is associated with increased subgenual ACC activation during reward processing in major depressive disorder.
    Omlor N; Richter M; Goltermann J; Steinmann LA; Kraus A; Borgers T; Klug M; Enneking V; Redlich R; Dohm K; Repple J; Leehr EJ; Grotegerd D; Kugel H; Bauer J; Dannlowski U; Opel N
    J Affect Disord; 2023 May; 329():404-412. PubMed ID: 36842646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
    Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
    Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression.
    Jing Y; Kalsekar I; Curkendall SM; Carls GS; Bagalman E; Forbes RA; Hebden T; Thase ME
    Clin Ther; 2011 Sep; 33(9):1246-57. PubMed ID: 21840058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting.
    Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS
    Int Clin Psychopharmacol; 2014 Mar; 29(2):116-9. PubMed ID: 24108149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder.
    Bauer M; Thase ME; Liu S; Earley W; Eriksson H
    J Psychopharmacol; 2015 May; 29(5):565-74. PubMed ID: 25257148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
    Simon JS; Nemeroff CB
    J Clin Psychiatry; 2005 Oct; 66(10):1216-20. PubMed ID: 16259533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.
    Han C; Wang SM; Kato M; Lee SJ; Patkar AA; Masand PS; Pae CU
    Expert Rev Neurother; 2013 Jul; 13(7):851-70. PubMed ID: 23898855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of augmentation strategies for patients with major depressive disorder.
    Fleurence R; Williamson R; Jing Y; Kim E; Tran QV; Pikalov AS; Thase ME
    Psychopharmacol Bull; 2009; 42(3):57-90. PubMed ID: 19752841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression.
    Kato M; Chang CM
    CNS Drugs; 2013 May; 27 Suppl 1():S11-9. PubMed ID: 23709358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.